EMEA-002269-PIP01-17

Key facts

Invented name
Lynparza
Active substance
Olaparib
Therapeutic area
Oncology
Decision number
P/0262/2018
PIP number
EMEA-002269-PIP01-17
Pharmaceutical form(s)
  • Capsule, hard
  • Age appropriate oral solid dosage form
  • Tablet
Condition(s) / indication(s)
Treatment of all conditions included in the category of malignant neoplasms (except central nervous system tumours, haematopoietic and lymphoid tissue neoplasms)
Route(s) of administration
Oral use
Contact for public enquiries
AstraZeneca AB

E-mail: paediatrics@astrazeneca.com
Tel.+46 855327591

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating